VYTRUS BIOTECH EO -01 - Asset Resilience Ratio
VYTRUS BIOTECH EO -01 (V5P) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how VYTRUS BIOTECH EO -01's Asset Resilience Ratio has changed over time. See V5P FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down VYTRUS BIOTECH EO -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of VYTRUS BIOTECH EO -01.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €600.00 | 0.0% |
| Total Liquid Assets | €600.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: VYTRUS BIOTECH EO -01 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
VYTRUS BIOTECH EO -01 Industry Peers by Asset Resilience Ratio
Compare VYTRUS BIOTECH EO -01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for VYTRUS BIOTECH EO -01 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for VYTRUS BIOTECH EO -01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €600.00 ≈ $701.46 |
€14.66 Million ≈ $17.14 Million |
0.00pp |
| 2024-12-31 | 0.01% | €600.00 ≈ $701.46 |
€11.13 Million ≈ $13.01 Million |
0.00pp |
| 2023-12-31 | 0.01% | €600.00 ≈ $701.46 |
€9.31 Million ≈ $10.89 Million |
0.00pp |
| 2021-12-31 | 0.01% | €522.14 ≈ $610.44 |
€7.18 Million ≈ $8.40 Million |
-- |
About VYTRUS BIOTECH EO -01
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more